Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Infusion of MSC · 1 trial · 1 indication
Incidence of adverse reactions grade 3 and 4 according to DAIDs scale
Changes in CD4+ cell count and CD4+/CD8+ ratio as measured by flow citometry
| Arm | Type | Description |
|---|---|---|
| Mesenchymal stem cells | EXPERIMENTAL | Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue |
| Placebo | PLACEBO_COMPARATOR | Intravenous infusion of 4 doses of Placebo |
| Name | Type | Description |
|---|---|---|
| Infusion of MSC | DRUG | Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20). |
| Infusion of placebo | DRUG | Infusion of placebo (weeks 0-4-8-20) |
Inclusion Criteria: * Confirmed HIV infection * Age\> 18 years, both sexes * In treatment with antiretroviral therapy (ART) * Sustained HIV viral load \<50 copies / ml for ≥ 1 years prior to study entry * CD4 + cell count \< 350/mL * Immunological discordant response defined as: an increase \<75 or...
Infusion of MSC is an investigational small molecule being studied for the treatment of Discordant Immunological Response in HIV Infected Subjects. It is being developed by Design Therapeutics, Inc. (NASDAQ: DSGN) and is currently in Phase 1 clinical development.
Infusion of MSC is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker DSGN. The drug is in Phase 1 clinical development for Discordant Immunological Response in HIV Infected Subjects.
Infusion of MSC is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial for this drug has been completed.
Infusion of MSC has one completed clinical trial, NCT02290041, titled "Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response." This Phase 1 trial enrolled 5 participants in Spain and was placebo-controlled, randomized, and double-blind.
Infusion of MSC is the drug name used in the clinical trial NCT02290041. The trial title refers to treatment with MSC in HIV-infected patients. The drug is being developed by Design Therapeutics, Inc. for Discordant Immunological Response in HIV Infected Subjects.